JP2013525306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525306A5 JP2013525306A5 JP2013505159A JP2013505159A JP2013525306A5 JP 2013525306 A5 JP2013525306 A5 JP 2013525306A5 JP 2013505159 A JP2013505159 A JP 2013505159A JP 2013505159 A JP2013505159 A JP 2013505159A JP 2013525306 A5 JP2013525306 A5 JP 2013525306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- cancer
- polysaccharide
- uronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 79
- 150000004676 glycans Chemical class 0.000 claims description 41
- 238000009472 formulation Methods 0.000 claims description 28
- 229920001282 polysaccharide Polymers 0.000 claims description 27
- 239000005017 polysaccharide Substances 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 22
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 16
- 150000004804 polysaccharides Polymers 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 230000001858 anti-Xa Effects 0.000 claims description 5
- 150000008273 hexosamines Chemical group 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 125000000600 disaccharide group Chemical group 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 7
- 230000037361 pathway Effects 0.000 claims 5
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 4
- 229940123237 Taxane Drugs 0.000 claims 4
- 229940028652 abraxane Drugs 0.000 claims 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 229960005277 gemcitabine Drugs 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 150000003230 pyrimidines Chemical class 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- VXNQMUVMEIGUJW-XNOMRPDFSA-L disodium;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 VXNQMUVMEIGUJW-XNOMRPDFSA-L 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 108090000031 Hedgehog Proteins Proteins 0.000 claims 1
- 102000003693 Hedgehog Proteins Human genes 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- GSOXMQLWUDQTNT-WAYWQWQTSA-N [3-methoxy-2-phosphonooxy-6-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 GSOXMQLWUDQTNT-WAYWQWQTSA-N 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 claims 1
- -1 buddy mezan Chemical compound 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 229950003600 ombrabulin Drugs 0.000 claims 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 claims 1
- 229950011498 plinabulin Drugs 0.000 claims 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 229950008737 vadimezan Drugs 0.000 claims 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 4
- 239000003055 low molecular weight heparin Substances 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000014508 negative regulation of coagulation Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- MCHWWJLLPNDHGL-KVTDHHQDSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-3,4-diol Chemical group OC[C@H]1O[C@H](CO)[C@@H](O)[C@@H]1O MCHWWJLLPNDHGL-KVTDHHQDSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/762,268 | 2010-04-16 | ||
| US12/762,268 US8592393B2 (en) | 2007-11-02 | 2010-04-16 | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| PCT/US2011/032581 WO2011130572A1 (en) | 2010-04-16 | 2011-04-14 | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525306A JP2013525306A (ja) | 2013-06-20 |
| JP2013525306A5 true JP2013525306A5 (enExample) | 2014-05-29 |
Family
ID=44799388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505159A Pending JP2013525306A (ja) | 2010-04-16 | 2011-04-14 | 前駆細胞動員を伴う疾患の治療および予防のための多糖組成物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8592393B2 (enExample) |
| EP (1) | EP2558124A4 (enExample) |
| JP (1) | JP2013525306A (enExample) |
| CN (1) | CN103096924A (enExample) |
| CA (1) | CA2796063A1 (enExample) |
| WO (1) | WO2011130572A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| ES2567079T3 (es) | 2007-11-02 | 2016-04-19 | Momenta Pharmaceuticals, Inc. | Composiciones de polisacáridos que no son anticoagulantes |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| CN102985443B (zh) | 2010-04-16 | 2017-05-10 | 动量制药公司 | 组织靶向 |
| WO2011159770A2 (en) | 2010-06-17 | 2011-12-22 | Momenta Pharmaceuticals, Inc. | Methods and compositions for modulating hair growth |
| US9351943B2 (en) * | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
| US20140351961A1 (en) * | 2011-08-31 | 2014-11-27 | Alexzander A. Asea | Compositions and methods for treatment of metastatic cancer |
| WO2013095215A1 (en) * | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| SMT201800143T1 (it) * | 2011-12-19 | 2018-05-02 | Dilafor Ab | Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico |
| CA2910837A1 (en) | 2013-05-28 | 2014-12-04 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
| GB2515315A (en) | 2013-06-19 | 2014-12-24 | Dilafor Ab | New Processes |
| CA2975410A1 (en) * | 2015-04-07 | 2016-10-13 | Immunomedics, Inc. | Y-90-labeled anti-cd22 antibody (epratuzumab tetraxetan) in refractory/relapsed adult cd22+ b-cell acute lymphoblastic leukemia |
| US20190201556A1 (en) | 2016-05-16 | 2019-07-04 | Mtm Research, Llc | Fluorochemical targeted therapies |
| US10849995B2 (en) * | 2017-05-09 | 2020-12-01 | Crosby Innovations, LLC | Handheld sanitizing device |
| CA3104821A1 (en) | 2018-05-07 | 2019-11-14 | Mtm Research, Llc | Photodynamic compositions and methods of use |
| CN109248171A (zh) * | 2018-09-13 | 2019-01-22 | 黄泳华 | 含有伊马替尼与植物多糖的组合物 |
| CN109010354A (zh) * | 2018-09-15 | 2018-12-18 | 黄泳华 | 含有伊马替尼与植物多糖的组合物 |
| CN112949370A (zh) | 2019-12-10 | 2021-06-11 | 托比股份公司 | 眼睛事件检测 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE620906A (enExample) | ||||
| US3118816A (en) | 1962-04-03 | 1964-01-21 | Abbott Lab | N-succinyl heparin and process |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| CA1136620A (en) | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| FR2538404B1 (enExample) | 1982-12-28 | 1985-08-23 | Anic Spa | |
| IT1195497B (it) | 1983-03-08 | 1988-10-19 | Opocrin Spa | Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina |
| FR2553287B1 (fr) | 1983-10-18 | 1986-09-12 | Choay Sa | Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire |
| IT1169888B (it) | 1983-10-25 | 1987-06-03 | Italfarmaco Spa | Glicosaminoglicani modificati dotati di attivita' antitrombotica |
| US4847338A (en) | 1985-03-28 | 1989-07-11 | University Of Iowa Research Foundation | Low molecular weight heparin fragments as inhibitors of complement activation |
| US4916219A (en) | 1985-03-28 | 1990-04-10 | University Of Iowa Research Foundation | Oligosaccharide heparin fragments as inhibitors of complement cascade |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5262403A (en) | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
| US5541166A (en) | 1987-01-23 | 1996-07-30 | The Australian National University | Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity |
| US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| FR2614026B1 (fr) | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
| KR920700232A (ko) | 1988-06-03 | 1992-02-19 | 원본미기재 | 글리코사미노글리칸 염류, 그 제조방법 및 이를 함유하는 제약 조성물 |
| IL86753A0 (en) | 1988-06-15 | 1988-11-30 | Hadassah Med Org | Pharmaceutical compositions for treatment of lupus |
| DK191889D0 (da) | 1989-04-20 | 1989-04-20 | Bukh Meditec | Kosmetisk middel |
| SE9002550D0 (sv) | 1990-08-01 | 1990-08-01 | Kabivitrum Ab | Heparinfragment |
| IT1243987B (it) | 1990-10-29 | 1994-06-28 | Derivati Organici Lab | Procedimento per la preparazione di epossi-eparidi prodotti ottenuti ecomposizioni farmaceutiche che li contengono |
| US5250519A (en) | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| US5280016A (en) | 1991-03-29 | 1994-01-18 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| SE9101155D0 (sv) | 1991-04-18 | 1991-04-18 | Kabi Pharmacia Ab | Novel heparin derivatives |
| IT1254216B (it) | 1992-02-25 | 1995-09-14 | Opocrin Spa | Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
| US5668118A (en) | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| US5296471A (en) | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
| US5696100A (en) | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| PT690720E (pt) | 1993-03-12 | 2001-12-28 | Xoma Technology Ltd | Utilizacoes terapeuticas de produtos de proteina bactericida indutora de permeabilidade |
| IT1264709B1 (it) | 1993-07-12 | 1996-10-04 | Italfarmaco Spa | Derivati eparinici ad attivita' antimetastatica |
| US5583121A (en) | 1994-01-12 | 1996-12-10 | Michigan State University | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| US6127347A (en) | 1994-01-12 | 2000-10-03 | Univ Michigan | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| WO1995030424A1 (en) | 1994-05-06 | 1995-11-16 | Glycomed Incorporated | O-desulfated heparin derivatives, methods of making and uses thereof |
| EP1371666B1 (en) | 1994-07-01 | 2007-08-15 | Seikagaku Corporation | Use of desulfated heparin |
| US5733893A (en) | 1995-03-15 | 1998-03-31 | Washington University | Method of identifying molecules that regulate FGF activity |
| US6001820A (en) | 1995-03-31 | 1999-12-14 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| GB2299998B (en) * | 1995-03-31 | 1997-03-26 | Hamilton Civic Hospitals Res | Compositions for inhibiting thrombogenesis |
| US5744457A (en) | 1995-03-31 | 1998-04-28 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
| US5690910A (en) | 1995-08-18 | 1997-11-25 | Baker Norton Pharmaceuticals, Inc. | Method for treating asthma |
| US5990097A (en) | 1996-07-29 | 1999-11-23 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
| US5767269A (en) | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
| AUPO573697A0 (en) | 1997-03-20 | 1997-04-10 | Prince Henry's Institute Of Medical Research | Diagnosis of endometrial cancer |
| US6596705B1 (en) | 1998-02-09 | 2003-07-22 | The Regents Of The University Of California | Inhibition of L-selectin and P-selection mediated binding using heparin |
| US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| CN1197587C (zh) | 2000-06-09 | 2005-04-20 | 中国科学院上海细胞生物学研究所 | N－位脱硫酸肝素在预防和治疗炎症中的应用 |
| US6514866B2 (en) | 2001-01-12 | 2003-02-04 | North Carolina State University | Chemically enhanced focused ion beam micro-machining of copper |
| BRPI0101486B1 (pt) | 2001-04-17 | 2017-09-19 | Cristália Produtos Químicos Farmacêuticos Ltda. | Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns |
| CZ307433B6 (cs) | 2001-09-12 | 2018-08-22 | Leadiant Biosciences Sa | Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení |
| WO2003078960A2 (en) | 2002-03-11 | 2003-09-25 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
| JP2006501815A (ja) | 2002-04-25 | 2006-01-19 | モメンタ ファーマシューティカルズ インコーポレイテッド | 粘膜送達のための方法および製品 |
| US8071569B2 (en) | 2002-09-20 | 2011-12-06 | Mousa Shaker A | Oxidized heparin fractions and their use in inhibiting angiogenesis |
| US7964439B2 (en) | 2002-12-20 | 2011-06-21 | The Trustees Of Princeton University | Methods of fabricating devices by transfer of organic material |
| CA2525854C (en) | 2003-05-20 | 2009-12-15 | Genentech, Inc. | Acylsulfamide inhibitors of factor viia |
| WO2005032483A2 (en) | 2003-10-01 | 2005-04-14 | Momenta Pharmaceuticals, Inc. | Polysaccharides for pulmonary delivery of active agents |
| FR2866650B1 (fr) | 2004-02-24 | 2006-04-28 | Aventis Pharma Sa | Oligosaccharides, procede de preparation, utilisation et compositions pharmaceutiques les renfermant |
| US20050282775A1 (en) | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
| US20060040896A1 (en) | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| US7767420B2 (en) | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
| WO2007059313A1 (en) | 2005-11-16 | 2007-05-24 | Children's Medical Center Corporation | Method to assess breast cancer risk |
| EP2447285A3 (en) | 2006-05-25 | 2013-01-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
| EP1867995A1 (en) | 2006-06-15 | 2007-12-19 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring metastasized bladder cancer using the determination of MMP-7 in the circulation of patients |
| WO2007149938A2 (en) | 2006-06-21 | 2007-12-27 | The Salk Institute Biological Studies | Methods for promoting hair growth |
| JP4964577B2 (ja) | 2006-12-15 | 2012-07-04 | 有限会社応用糖質化学研究所 | 親脂質性ヘパリン修飾体、その製造方法及び毛髪成長促進剤 |
| FR2912409B1 (fr) | 2007-02-14 | 2012-08-24 | Sanofi Aventis | Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation |
| US8088753B2 (en) | 2007-06-29 | 2012-01-03 | Mediplex Corporation, Korea | Heparin conjugates and methods |
| US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
| WO2009007224A1 (en) | 2007-07-10 | 2009-01-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Low molecular weight heparin derivatives having neuroprotective activity |
| AU2008318343B2 (en) | 2007-11-02 | 2013-07-18 | Dilafor Ab | Non-anticoagulant polysaccharide compositions |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009105522A1 (en) | 2008-02-20 | 2009-08-27 | Momenta Pharmaceuticals, Inc. | Methods of making low molecular weight heparin compositions |
| CN102105133B (zh) | 2008-07-21 | 2015-06-17 | 奥德纳米有限公司 | 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法 |
| US20100331746A1 (en) | 2009-02-20 | 2010-12-30 | Aventis Pharma S.A. | Method of using enoxaparin for reducing the risk of death in acutely ill medical patients |
| US8435795B2 (en) | 2010-01-19 | 2013-05-07 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
-
2010
- 2010-04-16 US US12/762,268 patent/US8592393B2/en active Active
-
2011
- 2011-04-14 CA CA2796063A patent/CA2796063A1/en not_active Abandoned
- 2011-04-14 CN CN2011800293971A patent/CN103096924A/zh active Pending
- 2011-04-14 JP JP2013505159A patent/JP2013525306A/ja active Pending
- 2011-04-14 WO PCT/US2011/032581 patent/WO2011130572A1/en not_active Ceased
- 2011-04-14 EP EP20110769624 patent/EP2558124A4/en not_active Withdrawn
-
2013
- 2013-09-27 US US14/039,801 patent/US9212233B2/en active Active
-
2015
- 2015-11-09 US US14/935,549 patent/US20160060366A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525306A5 (enExample) | ||
| RU2010122324A (ru) | Полисахаридные композиции, не обладающие антикоагулянтными свойствами | |
| US8569262B2 (en) | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization | |
| Casu et al. | Re-visiting the structure of heparin | |
| US8592393B2 (en) | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization | |
| JP5371167B2 (ja) | 抗脈管形成活性を有し、かつ、抗凝固作用がない、部分脱硫酸グリコサミノグリカンの誘導体 | |
| EP2343077B1 (en) | Derivatives of totally N-desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | |
| RU2005113987A (ru) | Смесь полисахаридов, являющихся производными гепарина, их получение и фармацевтические композиции, их содержащие | |
| PT789777E (pt) | Polissacaridos que possuem um elevado teor de acido iduronico | |
| RU2014129816A (ru) | Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение | |
| JP2015500387A5 (enExample) | ||
| JP2009538386A5 (enExample) | ||
| SI2794667T1 (en) | Low anticoagulant heparins | |
| JP2003523460A5 (enExample) | ||
| JP2015500388A5 (enExample) | ||
| JP2020510119A5 (enExample) | ||
| Jin et al. | Structural analysis of a glucoglucuronan derived from laminarin and the mechanisms of its anti-lung cancer activity | |
| Casu | Structure and active domains of heparin | |
| RU2009134188A (ru) | Низкомолекулярные гепарины, имеющие по меньшей мере одну ковалентную связь с биотином или производным биотина, способ их получения и их применение | |
| RU2014143008A (ru) | Способ лечения остановки родов | |
| WO2005092929A8 (en) | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use | |
| JPH10218902A5 (enExample) | ||
| JP2005536577A (ja) | Ｎ−アシル−（エピ）ｋ５−アミン−ｏ−硫酸塩誘導体の製造方法およびｎ−アシル−（エピ）ｋ５−アミン−ｏ−硫酸塩誘導体 | |
| JP2006528614A5 (enExample) | ||
| RU2006105384A (ru) | Смеси олигосахаридов, являющихся производными гепарина, способ их получения и содержащие их фармацевтические композиции |